HYSI, ALBANA
 Distribuzione geografica
Continente #
NA - Nord America 203
EU - Europa 127
AS - Asia 86
AF - Africa 1
Totale 417
Nazione #
US - Stati Uniti d'America 203
CN - Cina 33
TR - Turchia 33
IE - Irlanda 30
SE - Svezia 28
UA - Ucraina 23
IT - Italia 19
GB - Regno Unito 13
DE - Germania 8
IN - India 6
VN - Vietnam 6
FR - Francia 3
IR - Iran 3
MY - Malesia 3
FI - Finlandia 2
IL - Israele 1
KZ - Kazakistan 1
RO - Romania 1
SN - Senegal 1
Totale 417
Città #
Chandler 42
Jacksonville 35
Dublin 30
Izmir 20
Dearborn 19
Nanjing 13
Princeton 12
Southend 10
Ashburn 8
Beijing 8
Wilmington 7
Woodbridge 7
Altamura 6
Cambridge 6
Dong Ket 6
Boardman 5
Ardabil 3
Kuala Lumpur 3
Leawood 3
Nanchang 3
Seattle 3
Ann Arbor 2
Augusta 2
Grevenbroich 2
Los Angeles 2
Monmouth Junction 2
New York 2
Norwalk 2
Washington 2
Buffalo 1
Changchun 1
Changsha 1
Chicago 1
Chieti 1
Dakar 1
Guangzhou 1
Hangzhou 1
Hebei 1
Houston 1
Jiaxing 1
Kunming 1
Oral 1
Quzhou 1
San Mateo 1
Shenyang 1
Udine 1
Totale 282
Nome #
Effect of maternal exposure to endocrine disrupting chemicals on reproduction and mammary gland development in female sprague-dawley rats. 83
Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor 83
The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis 74
The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells 72
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib 63
null 59
Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor 9
Totale 443
Categoria #
all - tutte 1.340
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.340


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 0 0 1 24
2019/202090 24 9 1 1 13 12 10 4 0 10 6 0
2020/202153 5 0 16 0 1 9 0 0 0 1 12 9
2021/202217 0 0 0 0 0 0 0 0 1 2 6 8
2022/2023125 8 22 10 10 15 16 9 8 17 5 2 3
2023/202445 1 1 5 2 4 12 14 3 1 2 0 0
Totale 443